MedTrace Logo

Primary and Secondary Hemostasis in Elective Coronary Artery Bypass Graft Surgery

NCT00825981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2010-07-23

No results posted yet for this study

Summary

Patients undergoing elective coronary artery bypass graft surgery (CABG) are treated with platelet inhibitors to reduce myocardial infarction and mortality.However, this can increase perioperative bleeding. A retrospective analysis of the data in our institution has revealed a significant increase in transfusion requirements after elective CABG since 5 years. The aim of our study is to observe if this increase in transfusion requirements is due to platelet inhibitors or due to other coagulation abnormalities resulting from other anticoagulants.

Conditions

  • Coronary Disease

Interventions

OTHER

screening coagulation abnormalities

if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-01-31
Completion
2010-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825981 on ClinicalTrials.gov